
|Videos|August 30, 2021
Analyzing GEMINI 1 clinical trial results of presbyopia eye drop
Author(s)Sheryl Stevenson, Alex Delaney-Gesing
George O. Waring IV, MD, FACS, discusses the latest results from the GEMINI 1 clinical trial of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Advertisement
George O. Waring IV, MD, FACS, of the Waring Vision Institute (Mount Pleasant, SC), discusses the latest results from the GEMINI 1 clinical trial (by Allergan, an Abbvie company) of AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
REGENXBIO completes enrollment in ATMOSPHERE and ASCENT trials of sura-vec in wet AMD
2
Increasing the knowledge base of GA is key to individualizing patient therapy
3
AAO 2025: Technician training platform expands education opportunities in ophthalmology
4
Quantifying intermittent retinal capillary perfusion in RVO and PDR
5